{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:01:22Z","timestamp":1789974082345,"version":"4.0.1"},"reference-count":53,"publisher":"China Science Publishing & Media Ltd.","issue":"9","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.3724\/abbs.2025194","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T10:14:16Z","timestamp":1760350456000},"page":"2070-2085","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["MLN4924 promotes the transcriptional activation of BTG2 via the ROS\/EGR1-mediated signaling axis to suppress acute myeloid leukemia progression"],"prefix":"10.3724","volume":"58","author":[{"given":"Xiao","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujuan","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"De Kouchkovsky I","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J, 2016, 6:","journal-title":"Blood Cancer J"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"Shimony S","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol, 2025, 100: 860-891.","journal-title":"Am J Hematol"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"Liu H","year":"2021","unstructured":"Liu H. Emerging agents and regimens for AML. J Hematol Oncol, 2021, 14:","journal-title":"J Hematol Oncol"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"Soleimani Samarkhazan H","year":"2025","unstructured":"Soleimani Samarkhazan H, Zehtabcheh S, Seraji HR, Beqaj SH, Tayefeh S, Mohammadi MH, Aghaei M. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res, 2025, 13:","journal-title":"Biomark Res"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood-2018-02-829051","volume":"131","author":"Fathi AT","year":"2018","unstructured":"Fathi AT. Pevonedistat, a new partner for 5-azacitidine. Blood, 2018, 131: 1391-1392.","journal-title":"Blood"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/cdd.2017.160","volume":"25","author":"Ai TJ","year":"2018","unstructured":"Ai TJ, Sun JY, Du LJ, Shi C, Li C, Sun XN, Liu Y. Inhibition of neddylation by MLN4924 improves neointimal hyperplasia and promotes apoptosis of vascular smooth muscle cells through p53 and p62. Cell Death Differ, 2018, 25: 319-329.","journal-title":"Cell Death Differ"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/14756366.2022.2136173","volume":"38","author":"Fu DJ","year":"2023","unstructured":"Fu DJ, Wang T. Discovery of dual tubulin-NEDDylation inhibitors with antiproliferative activity. J Enzyme Inhibition Med Chem, 2023, 38: 166-175.","journal-title":"J Enzyme Inhibition Med Chem"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1016\/j.apsb.2021.07.012","volume":"11","author":"Li Y","year":"2021","unstructured":"Li Y, Wang C, Xu T, Pan P, Yu Q, Xu L, Xiong X. Discovery of a small molecule inhibitor of cullin neddylation that triggers ER stress to induce autophagy. Acta Pharm Sin B, 2021, 11: 3567-3584.","journal-title":"Acta Pharm Sin B"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"1600089","DOI":"10.1002\/pmic.201600089","volume":"17","author":"Matondo M","year":"2017","unstructured":"Matondo M, Marcellin M, Chaoui K, Bousquet\u2010Dubouch M\u2010, Gonzalez\u2010de\u2010Peredo A, Monsarrat B, Burlet\u2010Schiltz O. Determination of differentially regulated proteins upon proteasome inhibition in AML cell lines by the combination of large-scale and targeted quantitative proteomics. Proteomics, 2017, 17:","journal-title":"Proteomics"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.apsb.2019.09.005","volume":"10","author":"Yu Q","year":"2020","unstructured":"Yu Q, Jiang Y, Sun Y. Anticancer drug discovery by targeting cullin neddylation. Acta Pharm Sin B, 2020, 10: 746-765.","journal-title":"Acta Pharm Sin B"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"10310","DOI":"10.1158\/0008-5472.CAN-10-2062","volume":"70","author":"Lin JJ","year":"2010","unstructured":"Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res, 2010, 70: 10310-10320.","journal-title":"Cancer Res"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/1535-7163.MCT-17-0083","volume":"17","author":"Vanderdys V","year":"2018","unstructured":"Vanderdys V, Allak A, Guessous F, Benamar M, Read PW, Jameson MJ, Abbas T. The neddylation inhibitor pevonedistat (MLN4924) suppresses and radiosensitizes head and neck squamous carcinoma cells and tumors. Mol Cancer Ther, 2018, 17: 368-380.","journal-title":"Mol Cancer Ther"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3324\/haematol.2020.272609","volume":"107","author":"Cojocari D","year":"2022","unstructured":"Cojocari D, Smith BN, Purkal JJ, Arrate MP, Huska JD, Xiao Y, Gorska A. Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia. Haematologica, 2022, 107: 825-835.","journal-title":"Haematologica"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-023-01476-8","volume":"16","author":"Short NJ","year":"2023","unstructured":"Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y. A phase 1\/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol, 2023, 16:","journal-title":"J Hematol Oncol"},{"key":"CITATION15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285014","author":"Murthy GSG","year":"2020","unstructured":"Murthy GSG, Saliba AN, Szabo A, Harrington A, Abedin S, Carlson K, Michaelis L. A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed\/refractory acute myeloid leukemia. Haematologica, 2020,","journal-title":"Haematologica"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","volume":"22","author":"Cheung EC","year":"2022","unstructured":"Cheung EC, Vousden KH. The role of ROS in tumour development and progression. Nat Rev Cancer, 2022, 22: 280-297.","journal-title":"Nat Rev Cancer"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12964-020-00576-z","volume":"18","author":"Liang Y","year":"2020","unstructured":"Liang Y, Jiang Y, Jin X, Chen P, Heng Y, Cai L, Zhang W. Neddylation inhibition activates the protective autophagy through NF-\u03baB-catalase-ATF3 axis in human esophageal cancer cells. Cell Commun Signal, 2020, 18:","journal-title":"Cell Commun Signal"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","volume":"115","author":"Swords RT","year":"2010","unstructured":"Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood, 2010, 115: 3796-3800.","journal-title":"Blood"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","volume":"19","author":"Bushweller JH","year":"2019","unstructured":"Bushweller JH. Targeting transcription factors in cancer - from undruggable to reality. Nat Rev Cancer, 2019, 19: 611-624.","journal-title":"Nat Rev Cancer"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","volume":"22","author":"Vervoort SJ","year":"2022","unstructured":"Vervoort SJ, Devlin JR, Kwiatkowski N, Teng M, Gray NS, Johnstone RW. Targeting transcription cycles in cancer. Nat Rev Cancer, 2022, 22: 5-24.","journal-title":"Nat Rev Cancer"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1038\/s41388-019-0873-8","volume":"38","author":"Li L","year":"2019","unstructured":"Li L, Ameri AH, Wang S, Jansson KH, Casey OM, Yang Q, Beshiri ML. EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. Oncogene, 2019, 38: 6241-6255.","journal-title":"Oncogene"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"e12922","DOI":"10.1111\/cpr.12922","volume":"54","author":"Ma Z","year":"2021","unstructured":"Ma Z, Gao X, Shuai Y, Wu X, Yan Y, Xing X, Ji J. EGR1-mediated linc01503 promotes cell cycle progression and tumorigenesis in gastric cancer. Cell Prolif, 2021, 54:","journal-title":"Cell Prolif"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/carcin\/22.9.1577","volume":"22","author":"Paulsson B","year":"2001","unstructured":"Paulsson B. The multiplicative model for cancer risk assessment: applicability to acrylamide. Carcinogenesis, 2001, 22:","journal-title":"Carcinogenesis"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.celrep.2019.04.101","volume":"27","author":"Schmidt K","year":"2019","unstructured":"Schmidt K, Carroll JS, Yee E, Thomas DD, Wert-Lamas L, Neier SC, Sheynkman G. The lncRNA SLNCR recruits the androgen receptor to EGR1-bound genes in melanoma and inhibits expression of tumor suppressor p21. Cell Rep, 2019, 27: 2493-2507.e4.","journal-title":"Cell Rep"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood-2013-07-517953","volume":"123","author":"Stoddart A","year":"2014","unstructured":"Stoddart A, Fernald AA, Wang J, Davis EM, Karrison T, Anastasi J, Le Beau MM. Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood, 2014, 123: 1069-1078.","journal-title":"Blood"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"BSR20220994","DOI":"10.1042\/BSR20220994","volume":"42","author":"Chen Y","year":"2022","unstructured":"Chen Y, Sun L. Inhibition of NEDD8 NEDDylation induced apoptosis in acute myeloid leukemia cells via p53 signaling pathway. Biosci Rep, 2022, 42:","journal-title":"Biosci Rep"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.tranon.2019.01.001","volume":"12","author":"Guo N","year":"2019","unstructured":"Guo N, Azadniv M, Coppage M, Nemer M, Mendler J, Becker M, Liesveld J. Effects of neddylation and mTOR inhibition in acute myelogenous leukemia. Transl Oncol, 2019, 12: 602-613.","journal-title":"Transl Oncol"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1007\/s10753-025-02259-8","volume":"48","author":"Chen Y","year":"2025","unstructured":"Chen Y, Liu C, Tong J, He C, Ling X, Xiang J, Xue C. Inhibition of cullin3 neddylation alleviates diabetic retinopathy by activating Nrf2 signaling to combat ROS-induced oxidative stress and inflammation. Inflammation, 2025, 48: 3194-3205.","journal-title":"Inflammation"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"642547","DOI":"10.3389\/fonc.2021.642547","volume":"11","author":"Wang B","year":"2021","unstructured":"Wang B, Guo H, Yu H, Chen Y, Xu H, Zhao G. The role of the transcription factor EGR1 in cancer. Front Oncol, 2021, 11:","journal-title":"Front Oncol"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13045-023-01485-7","volume":"16","author":"Fu DJ","year":"2023","unstructured":"Fu DJ, Wang T. Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions. J Hematol Oncol, 2023, 16:","journal-title":"J Hematol Oncol"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","volume":"6","author":"Ad\u00e8s L","year":"2022","unstructured":"Ad\u00e8s L, Girshova L, Doronin VA, D\u00edez-Campelo M, Valc\u00e1rcel D, Kambhampati S, Viniou NA. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv, 2022, 6: 5132-5145.","journal-title":"Blood Adv"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41419-019-1860-2","volume":"10","author":"El-Mesery M","year":"2019","unstructured":"El-Mesery M, Rosenthal T, Rauert-Wunderlich H, Schreder M, St\u00fchmer T, Leich E, Schlosser A. The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death. Cell Death Dis, 2019, 10:","journal-title":"Cell Death Dis"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","volume":"116","author":"Milhollen MA","year":"2010","unstructured":"Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-\u03baB\u2013dependent lymphoma. Blood, 2010, 116: 1515-1523.","journal-title":"Blood"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"100839","DOI":"10.1016\/j.neo.2022.100839","volume":"34","author":"Yin L","year":"2022","unstructured":"Yin L, Zhang J, Sun Y. Early growth response-1 is a new substrate of the GSK3\u03b2-FBXW7 axis. Neoplasia, 2022, 34:","journal-title":"Neoplasia"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"107377","DOI":"10.1016\/j.phrs.2024.107377","volume":"208","author":"Liu N","year":"2024","unstructured":"Liu N, Wang S, Li M, Zhao N, Wang D, Zhang R, Yu M. BET degrader exhibits lower antiproliferative activity than its inhibitor via EGR1 recruiting septins to promote E2F1-3 transcription in triple-negative breast cancer. Pharmacol Res, 2024, 208:","journal-title":"Pharmacol Res"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/s41375-023-01989-8","volume":"37","author":"Garcia-Cuellar MP","year":"2023","unstructured":"Garcia-Cuellar MP, Akan S, Slany RK. A C\/ebp\u03b1 isoform specific differentiation program in immortalized myelocytes. Leukemia, 2023, 37: 1850-1859.","journal-title":"Leukemia"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1182\/blood-2007-01-068809","volume":"110","author":"Joslin JM","year":"2007","unstructured":"Joslin JM, Fernald AA, Tennant TR, Davis EM, Kogan SC, Anastasi J, Crispino JD. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood, 2007, 110: 719-726.","journal-title":"Blood"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/biom14070738","volume":"14","author":"Tang H","year":"2024","unstructured":"Tang H, Pang X, Li S, Tang L. The double-edged effects of MLN4924: rethinking anti-cancer drugs targeting the neddylation pathway. Biomolecules, 2024, 14:","journal-title":"Biomolecules"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13046-024-03120-w","volume":"43","author":"Wang B","year":"2024","unstructured":"Wang B, Wang Y, Wang W, Wang Z, Zhang Y, Pan X, Wen X. WTAP\/IGF2BP3 mediated m6A modification of the EGR1\/PTEN axis regulates the malignant phenotypes of endometrial cancer stem cells. J Exp Clin Cancer Res, 2024, 43:","journal-title":"J Exp Clin Cancer Res"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.cgt.7700896","volume":"13","author":"Baron V","year":"2006","unstructured":"Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGF\u03b21, PTEN, p53, and fibronectin. Cancer Gene Ther, 2006, 13: 115-124.","journal-title":"Cancer Gene Ther"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"177230","DOI":"10.1016\/j.ejphar.2024.177230","volume":"988","author":"Li Y","year":"2025","unstructured":"Li Y, He X, Li S, Chen S, Zhao Z, Mu Y, Zhao AZ. The phosphodiesterase-4 inhibitor Zl-n-91 suppresses glioblastoma growth via EGR1\/PTEN\/AKT pathway. Eur J Pharmacol, 2025, 988:","journal-title":"Eur J Pharmacol"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41419-023-05630-5","volume":"14","author":"Hong E","year":"2023","unstructured":"Hong E, Barczak W, Park S, Heo JS, Ooshima A, Munro S, Hong CP. Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-\u03b2 signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors. Cell Death Dis, 2023, 14:","journal-title":"Cell Death Dis"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1172\/JCI70297","volume":"124","author":"Li H","year":"2014","unstructured":"Li H, Tan M, Jia L, Wei D, Zhao Y, Chen G, Xu J. Inactivation of SAG\/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis. J Clin Invest, 2014, 124: 835-846.","journal-title":"J Clin Invest"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/cells14151207","volume":"14","author":"Nigam M","year":"2025","unstructured":"Nigam M, Punia B, Dimri DB, Mishra AP, Radu AF, Bungau G. Reactive oxygen species: a double-edged sword in the modulation of cancer signaling pathway dynamics. Cells, 2025, 14:","journal-title":"Cells"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"103807","DOI":"10.1016\/j.redox.2025.103807","volume":"86","author":"Lee SS","year":"2025","unstructured":"Lee SS, Yoo YC. NOX-NOS crosstalk in the liver-brain axis: novel insights for redox regulation and neurodegenerative diseases. Redox Biol, 2025, 86:","journal-title":"Redox Biol"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"155459","DOI":"10.1016\/j.phymed.2024.155459","volume":"126","author":"Chen Z","year":"2024","unstructured":"Chen Z, Wu F, Li J, Dong J, He H, Li X, Lu Q. Investigating the synergy of Shikonin and Valproic acid in inducing apoptosis of osteosarcoma cells via ROS-mediated EGR1 expression. Phytomedicine, 2024, 126:","journal-title":"Phytomedicine"},{"key":"CITATION47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bcp.2019.07.008","volume":"168","author":"Liu Y","year":"2019","unstructured":"Liu Y, Fan D. Ginsenoside Rg5 induces G2\/M phase arrest, apoptosis and autophagy via regulating ROS-mediated MAPK pathways against human gastric cancer. Biochem Pharmacol, 2019, 168: 285-304.","journal-title":"Biochem Pharmacol"},{"key":"CITATION48","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41419-020-2317-3","volume":"11","author":"Fan J","year":"2020","unstructured":"Fan J, Ren D, Wang J, Liu X, Zhang H, Wu M, Yang G.  Bruceine D induces lung cancer cell apoptosis and autophagy via the ROS\/MAPK signaling pathway in vitro and in vivo . Cell Death Dis, 2020, 11:","journal-title":"Cell Death Dis"},{"key":"CITATION49","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bcp.2018.11.003","volume":"162","author":"Wang LJ","year":"2019","unstructured":"Wang LJ, Lee YC, Huang CH, Shi YJ, Chen YJ, Pei SN, Chou YW. Non-mitotic effect of albendazole triggers apoptosis of human leukemia cells via SIRT3\/ROS\/p38 MAPK\/TTP axis-mediated TNF-\u03b1 upregulation. Biochem Pharmacol, 2019, 162: 154-168.","journal-title":"Biochem Pharmacol"},{"key":"CITATION50","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3892\/ol.2021.12565","volume":"21","author":"Chuang KC","year":"2021","unstructured":"Chuang KC, Chen FW, Tsai MH, Shieh JJ. EGR\u20111 plays a protective role in AMPK inhibitor compound C\u2011induced apoptosis through ROS\u2011induced ERK activation in skin cancer cells. Oncol Lett, 2021, 21:","journal-title":"Oncol Lett"},{"key":"CITATION51","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.lfs.2019.03.018","volume":"223","author":"Yang J","year":"2019","unstructured":"Yang J, Sun L, Han J, Zheng W, Peng W. DUSP1\/MKP-1 regulates proliferation and apoptosis in keratinocytes through the ERK\/Elk-1\/Egr-1 signaling pathway. Life Sci, 2019, 223: 47-53.","journal-title":"Life Sci"},{"key":"CITATION52","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.4161\/auto.21484","volume":"8","author":"Luo Z","year":"2012","unstructured":"Luo Z, Pan Y, Jeong LS, Liu J, Jia L. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells. Autophagy, 2012, 8: 1677-1679.","journal-title":"Autophagy"},{"key":"CITATION53","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1080\/01616412.2023.2176633","volume":"45","author":"Wu F","year":"2023","unstructured":"Wu F, Zhang P, Zhou G.  The involvement of EGR1 in neuron apoptosis in the in vitro model of spinal cord injury via BTG2 up-regulation . Neurol Res, 2023, 45: 646-654.","journal-title":"Neurol Res"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/F863E3E1F09847D3BAC6F9BF76E6ED86","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025194","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/F863E3E1F09847D3BAC6F9BF76E6ED86","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:18:28Z","timestamp":1789971508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,1,6]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2025194","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,6]]}}}